- Home
- FTH vs GUG Comparison
FTH vs GUG Comparison
Compare FTH & GUG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | FTH | GUG |
|---|---|---|
| Founded | 1999 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Trusts Except Educational Religious and Charitable |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 507.8M | 462.7M |
| IPO Year | 2021 | 2021 |
Fundamental Metrics
Financial Performance| Metric | FTH | GUG |
|---|---|---|
| Price | $21.84 | $14.10 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 15 | 0 |
| Target Price | ★ $55.31 | N/A |
| AVG Volume (30 Days) | ★ 351.3K | 92.8K |
| Earning Date | 11-03-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $16.57 | $13.55 |
| 52 Week High | $42.14 | $16.46 |
Technical Indicators
Market Signals| Indicator | FTH | GUG |
|---|---|---|
| Relative Strength Index (RSI) | 46.98 | 54.23 |
| Support Level | $16.57 | $13.55 |
| Resistance Level | $21.97 | $16.40 |
| Average True Range (ATR) | 2.02 | 0.17 |
| MACD | 0.65 | 0.06 |
| Stochastic Oscillator | 87.41 | 97.03 |
Price Performance
Historical ComparisonAbout FTH Faeth Therapeutics Inc. Common Stock
Faeth Therapeutics Inc is a clinical-stage biotechnology company focused on improving outcomes for cancer patients through multi-node inhibition of critical oncogenic pathways. The company's principal program is PIKTOR, an investigational all-oral combination of serabelisib and sapanisertib in development for endometrial and breast cancer.
About GUG Guggenheim Active Allocation Fund of Beneficial Interest
Guggenheim Active Allocation Fund is a diversified closed-end management investment company. The Fund's investment objective is to maximize total return through a combination of current income and capital appreciation. The Fund represents a single operating segment. Its products are Mutual Funds, Wealth Management SMAS, Institutional SMAS, ETFS, UITS, UCITS, CIT, Closed-End Funds, Private Funds, Rydex Funds, and Variable Insurance Funds.